SteelPeak Wealth LLC Lowers Holdings in Twist Bioscience Corporation $TWST

SteelPeak Wealth LLC trimmed its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 8.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 6,682 shares of the company’s stock after selling 646 shares during the period. SteelPeak Wealth LLC’s holdings in Twist Bioscience were worth $246,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after acquiring an additional 302 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its holdings in shares of Twist Bioscience by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 23,178 shares of the company’s stock worth $910,000 after buying an additional 612 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in Twist Bioscience by 6.3% in the 1st quarter. Allianz Asset Management GmbH now owns 17,000 shares of the company’s stock valued at $667,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in Twist Bioscience by 18.5% in the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company’s stock valued at $251,000 after purchasing an additional 1,006 shares in the last quarter.

Twist Bioscience Trading Down 2.7%

Shares of Twist Bioscience stock opened at $31.89 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. Twist Bioscience Corporation has a 1 year low of $24.07 and a 1 year high of $55.33. The company has a market capitalization of $1.92 billion, a P/E ratio of -21.99 and a beta of 2.38. The business has a 50 day moving average price of $27.68 and a 200 day moving average price of $32.75.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TWST. Barclays lowered their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Evercore ISI decreased their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Finally, Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Insider Buying and Selling

In other Twist Bioscience news, CFO Adam Laponis sold 5,875 shares of the business’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $189,116.25. Following the completion of the transaction, the chief financial officer directly owned 97,042 shares in the company, valued at approximately $3,123,781.98. The trade was a 5.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Paula Green sold 9,724 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $313,015.56. Following the completion of the transaction, the senior vice president owned 114,678 shares of the company’s stock, valued at $3,691,484.82. This trade represents a 7.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,851 shares of company stock worth $1,859,894 in the last three months. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.